Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
6
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
biotech
national top stories
new york blog main
rna interference
san francisco blog main
alnylam pharmaceuticals
atlas venture
deals
drugs
fda
gene therapy
patisiran
regeneron pharmaceuticals
san diego blog main
san francisco top stories
startups
acute hepatic porphyrias
adeno-associated virus
akcea therapeutics
akin akinc
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
aminolevulinic acid
arrowhead pharmaceuticals
astellas pharma
atopic dermatitis
audentes therapeutics
autoimmune disorders
avidity biosciences
barry greene
bluebird bio
boehringer ingelheim
boston university
What
ago
6
×
medicines
rna
therapeutics
alnylam
drug
fda
interference
long
medicine
rnai
years
abandoning
adding
address
adds
aiming
allosteric
approval
approve
awaits
baggage
balance
biological
biotechs
build
clinic
companies
considering
crossed
cuts
data
deal
decades
decibel
decision
development
dicerna
discovered
disease
Language
unset
Current search:
boston
×
ago
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision